Author: Joseph Gerard

Where Patient Data Goes After the Handoff: The Hidden HIPAA Risk in Care Coordination

Posted on by Joseph Gerard

Medicine insurance security care for life. Hospital diagnosis design, health care document filling concept. Document health diagnoses medical insurance. Text and cartoon character vector illustration

Written by Ryan Harris,

A patient can leave the hospital with new prescriptions, follow-up visits, and home care already being arranged. Before they’ve even settled back in at home, parts of their medical record may have been sent to several different providers and systems.

That kind of movement is routine in healthcare. Care often depends on people in different offices and organizations being able to share information without slowing things down.

The trouble starts when everyone knows where the information came from, but nobody is quite sure where all the copies went. A discharge summary becomes an attachment. The attachment gets downloaded. Someone uploads it into another portal. A case manager keeps a working copy because the referral isn’t finished yet. None of those actions looks especially risky on its own.

Put them together, though, and the patient record is suddenly much harder to follow.

A secure handoff doesn’t settle what happens next

Case managers deal with this constantly. Their job often involves getting the right information to the right person before a delay turns into a bigger problem. The role of a case manager can involve coordinating providers, reviewing care plans, handling referrals, speaking with insurers, and helping patients move between settings. That work produces a lot of legitimate data sharing.

Picture a fairly ordinary discharge. A hospital sends a summary to a rehabilitation facility through an approved system. The facility downloads the document, adds it to its own chart, and forwards part of the information to a pharmacy. Meanwhile, a case manager uploads supporting records to an insurer for authorization.

The first transfer may have been handled exactly as intended. That still leaves a long list of practical questions. Where is the downloaded copy now? Does the rehabilitation facility back up that folder automatically? Who can open it? Does the insurer’s portal keep attachments after the authorization closes? Is someone maintaining another copy while waiting for a response?

Organizations that rely on external infrastructure to store or process ePHI also need to know how their HIPAA-compliant cloud services handle access, backups, recovery, and the systems underneath the application staff actually see. Those details matter long after somebody clicks “send.”

The HIPAA Security Rule is concerned with electronic protected health information that is created, received, maintained, or transmitted. “Maintained” is easy to overlook. A record doesn’t stop being sensitive because nobody is actively using it today.

Healthcare workers usually notice the visible handoff. They remember the fax, portal message, referral, or phone call. The less visible part is what happens afterward, when the information settles into somebody else’s workflow.

One patient record can become six working copies

Most healthcare organizations don’t have one neat version of a patient record moving from place to place.

They have an official record and a collection of working copies around it.

A nurse may export a medication list before calling another provider. A case manager might keep a spreadsheet showing which referrals are still pending. A utilization review team may attach clinical notes to an authorization request. A home health agency could download a PDF because the referring hospital and its own software don’t communicate cleanly.

There’s nothing unusual about that. In fact, some of these steps are what keep care moving.

But copies tend to outlive the reason they were created.

The spreadsheet that was meant to last three days is still on a shared drive four months later. A former employee still has access to a referral portal because that account wasn’t tied into the normal offboarding process. A desktop folder contains discharge paperwork that was supposed to be temporary. None of these situations requires a sophisticated attack. They exist because healthcare work is busy, systems don’t always cooperate, and temporary fixes have a habit of becoming permanent.

That’s where privacy controls can look stronger on paper than they do in practice.

An organization can lock down its EHR pretty well and still have patient information drifting through smaller systems that get far less scrutiny. AIHCP’s discussion of patient confidentiality challenges touches on access controls and secure communication, but those safeguards only help if you know everywhere the information is ending up.

A better way to spot problems is to look at what actually happens during a discharge. A file might be downloaded for review, uploaded again to a referral portal, mentioned in an email, and copied into a tracking sheet while staff wait for a response. If that referral drags on for several days, those extra copies can easily stick around longer than anyone intended.

You’ll often learn more from that conversation than from a polished diagram of the organization’s approved systems.

Vendors make the trail harder to see

Healthcare organizations depend on outside companies for all kinds of ordinary functions. Billing, scheduling, cloud storage, transcription, analytics, messaging, document management, and case management software may all involve outside vendors.

Staff rarely see the full stack behind those services.

Suppose a behavioral health practice uses an online case management system. The practice deals with one company and sees one login screen. Behind that screen, the application may rely on another provider for infrastructure, another for backups, and another for automated communications.

That doesn’t mean anything improper is happening. It does mean the data trail is longer than the user interface suggests.

HHS guidance on business associates addresses situations where outside organizations perform functions involving protected health information. Subcontractors can also become part of those relationships. For the healthcare organization using the service, the practical concern is understanding who can touch the data and under what arrangement.

“We use a HIPAA-compliant vendor” isn’t a very revealing answer.

A better review gets specific. What information is the vendor receiving? Is it keeping the data or merely passing it through? Can vendor employees access production systems? Who controls backups? What happens to stored information when the contract ends? Does the service depend on additional companies that also handle ePHI?

The answers don’t all need to come from nurses or case managers. Most won’t. But frontline staff can identify something the legal and IT teams can’t always see from contracts: how the service is actually being used.

That matters because the official use and the real use aren’t always identical.

A system purchased for referrals may become a place where staff also upload discharge records. A shared portal intended for one department may slowly become useful to three others. A vendor can end up handling more patient information than anyone anticipated when the agreement was signed.

NIST’s guidance for implementing the HIPAA Security Rule places heavy emphasis on understanding risk rather than simply collecting controls. That distinction is important. You can’t judge the risk around a vendor very well if nobody knows what information staff are actually putting into the system.

The workaround is often telling you something

Some of the most revealing privacy conversations start with a sentence nobody wants to hear:

“I know we’re not supposed to do it this way, but…”

Maybe the referral portal goes down regularly, so employees found another way to send paperwork. Maybe the case management system doesn’t show everything staff need on one screen, so someone created a separate spreadsheet. Maybe clinicians take screenshots because two systems make it painfully difficult to compare information.

It’s easy to treat those situations as training failures.

Sometimes they are. Sometimes they’re workflow failures.

If ten employees keep doing the same workaround, there’s probably a reason. Telling them for the eleventh time that the approved process is the approved process may not change much if the approved process prevents them from getting a patient discharged before the end of the day.

That doesn’t mean unsafe shortcuts should be accepted. It means they’re worth investigating rather than merely policing.

AIHCP has already looked at HIPAA compliance in a digital healthcare environment, including issues involving cloud storage, portals, mobile technology, and outside vendors. Care coordination is where many of those systems collide. A patient’s information can move through several of them during a single episode of care.

Wrap-up takeaway

Most people involved in a patient’s care are trying to do the same thing: get the information where it needs to go without slowing care down. The problem is that every extra download, portal, vendor, and temporary file leaves another place to keep track of. Over time, those small decisions can create a data trail that nobody fully owns anymore. That’s worth paying attention to because the weak spot may not be the main system everyone watches closely. It may be the forgotten account or working file sitting just outside it. 

Author Bio:

Ryan Harris is a writer covering technology, workplace learning, and operational risk. He writes about how training, digital systems, and everyday workflows affect safety, privacy, and decision-making, with a focus on making complex professional topics clear and practical.

 

Please also review AIHCP’s Managed Health Care Certification program and CE courses see if it meets your academic and professional goals.  These programs are online and independent study and open to qualified professionals seeking a four year certification

Peptides and Exercise Recovery: What Current Research Can and Cannot Tell Us

Posted on by Joseph Gerard

Doctor, laptop and writing notes at night thinking about healthcare solution, idea or planning at hospital. Woman medical nurse working late in focus with notebook and computer for research at clinic.Written by Alex,

Recovery after strenuous resistance exercise or a soft-tissue injury is not a single event. It involves a sequence of overlapping biological processes. Mechanical loading can disrupt muscle proteins and connective tissue, alter local signaling, and trigger an inflammatory response. In the hours and days that follow, immune cells, fibroblasts, muscle cells, blood vessels, and components of the extracellular matrix participate in repair.

Muscle protein synthesis increases after resistance exercise, while injured tendons move through overlapping inflammatory, proliferative, and remodeling phases in which collagen is produced and reorganized. With repeated and appropriately dosed loading, these short-term responses contribute to longer-term tissue adaptation.

Peptides are frequently mentioned in discussions of this biology because the human body uses many peptide and protein signals to coordinate cellular activity. Hormones, growth factors, cytokines, and other signaling molecules can influence inflammation, vascular responses, protein turnover, and tissue remodeling. That observation is biologically relevant, but it does not establish that administering a separate peptide drug will accelerate recovery, heal an injury, or improve performance. Normal signaling inside the body and treatment with an externally administered compound are different scientific questions.

Why Peptides Are Not One Therapeutic Category

The word peptide describes a chemical structure a chain of amino acids not a uniform clinical effect. Different peptides act through different receptors and pathways, have different half-lives, and can produce very different effects depending on dose, tissue exposure, route of administration, and the health of the person receiving them.

Some peptide-based medicines have extensive clinical trial data and FDA-approved indications. Others remain investigational and have little reliable human evidence for the uses promoted online.

This distinction is especially relevant in exercise medicine. A plausible molecular mechanism is an early stage of research, not proof of a useful clinical outcome. A compound can alter angiogenesis, inflammatory mediators, fibroblast activity, or growth-factor signaling in a laboratory model without improving pain, physical function, return-to-activity time, reinjury risk, or long-term tissue integrity in people. Those outcomes require appropriately designed human studies.

BPC-157 Illustrates the Evidence Gap

BPC-157 is a 15-amino-acid peptide that has attracted attention for proposed effects on tendon, ligament, muscle, bone, and other tissues. Much of that interest originates from cell and animal experiments.

A 2025 systematic review of the orthopedic and sports-medicine literature identified 36 eligible studies, of which 35 were preclinical and only one was a clinical musculoskeletal study. That human report involved 12 patients receiving intra-articular treatment for chronic knee pain; seven reported relief lasting more than six months. The study was small and retrospective, however, and lacked the controlled design required to establish efficacy or characterize safety reliably.

A separate 2025 review reached a similar conclusion about the evidence gap. Although animal studies describe effects involving angiogenesis, fibroblast activity, inflammatory signaling, and tissue repair, the authors found only a very small number of human pilot studies across several unrelated clinical settings. Large, rigorous clinical trials capable of defining musculoskeletal benefits, adverse effects, appropriate dosing, and longer-term outcomes are lacking.

FDA materials provide another reason for caution when interpreting the available research. In 2026, the agency evaluated BPC-157 free base and BPC-157 acetate in connection with possible inclusion on the section 503A bulk drug substances list. FDA stated that neither form is a component of an FDA-approved drug and concluded that available clinical information was insufficient to characterize safety adequately.

Its review also discussed potential immunogenicity, peptide-related impurities, uncertainties surrounding active-ingredient characterization, and the lack of human data for several proposed routes of administration.

The FDA evaluation concerned a nominated use in ulcerative colitis rather than exercise recovery, so it should not be treated as a direct test of musculoskeletal effectiveness. It does demonstrate why questions about formulation, identity, human safety data, and regulatory status cannot be separated from clinical discussions of these compounds.

Why Animal Healing Data Cannot Be Assumed to Apply to Humans

Preclinical research is essential for identifying biological mechanisms and deciding which treatments deserve further investigation. Translation to clinical care, however, is not automatic.

An experimentally created tendon defect in a rodent is different from chronic human tendinopathy, a partial tear in a recreational athlete, or rehabilitation following surgical repair. Age, underlying health, injury severity, mechanical loading, and rehabilitation conditions can all alter recovery.

Dose is another major consideration. A quantity that produces a biological response in an animal cannot simply be converted into a human dose according to body weight. Absorption, metabolism, tissue distribution, clearance, and receptor activity can differ substantially between species. Route of administration also changes exposure: oral, subcutaneous, intravenous, intra-articular, nasal, and other routes cannot be assumed to produce equivalent effects or risks.

Study design adds further limitations. Animal experiments commonly use controlled injuries, relatively small samples, short observation periods, and laboratory endpoints such as histologic appearance, tensile strength, or expression of signaling molecules.

Clinical decision-making requires additional information. Patients and clinicians need to know whether treatment improves meaningful outcomes such as pain, mobility, function, return to activity, recurrence, and quality of life and whether adverse effects emerge after repeated or prolonged exposure. A favorable change in a microscopic marker does not by itself demonstrate better recovery for a patient.

When Patients Ask About Recovery Peptides

Patients increasingly arrive at appointments after encountering social-media discussions, clinic websites, commercial claims, and physician-authored or physician-reviewed resources such as peptide therapy guidance from Dr. Jonathan Snipes. A useful clinical response is to identify exactly what is being claimed and then place that information alongside the quality of the human evidence, available safety data, and the patient’s individual circumstances.

The first question is which compound the patient is actually considering. The specific chemical form, proposed dose, route of administration, and intended condition all matter. Clinicians can then ask whether evidence exists from controlled human studies for that particular indication or whether the rationale comes mainly from laboratory and animal experiments.

Regulatory status also deserves attention: an FDA-approved medication, an investigational substance, a compounded preparation, and a product purchased from an online supplier do not carry the same evidence or quality assurances.

Product quality is particularly relevant when the substance lacks an approved commercial drug formulation. Identity, purity, sterility, peptide-related impurities, storage conditions, and batch consistency can influence risk. FDA’s BPC-157 materials, for example, have noted concerns about characterization and inconsistent naming of related substances.

Medication history and medical conditions should also be reviewed rather than considering a recovery peptide in isolation. When human safety information is sparse, uncertainty extends to interactions, repeated exposure, immune reactions, and use in people with significant medical conditions. Injectable formulations raise additional questions about sterility and administration practices.

Just as important, the original musculoskeletal problem should be diagnosed. Persistent pain described as a tendon injury can arise from a partial tear, joint disease, referred pain, nerve involvement, stress injury, or another disorder requiring different management.

Beginning an experimental intervention without clarifying the diagnosis can complicate or delay appropriate imaging, rehabilitation, activity modification, or medical treatment.

Competitive athletes face an additional issue unrelated to whether a compound eventually proves medically useful. The 2026 World Anti-Doping Agency Prohibited List specifically names BPC-157 under S0, Non-Approved Substances, and prohibits it at all times, both in and out of competition. Athletes governed by anti-doping rules therefore need to consider eligibility and testing consequences independently of discussions about possible therapeutic effects.

Conclusion

Peptide science is biologically interesting because peptide and protein signals are part of the communication systems involved in inflammation, tissue repair, protein synthesis, vascular responses, and remodeling. Those physiological observations, however, do not establish the safety or effectiveness of administering a particular peptide as treatment.

Evidence must be evaluated compound by compound, for the specific indication and route being proposed. In the case of BPC-157, the preclinical musculoskeletal literature is substantially more developed than reliable human clinical evidence.

Exercise programming, adequate nutrition, accurate diagnosis of injuries, progressive rehabilitation, and appropriate medical care remain separate clinical considerations and should not be replaced by assumptions drawn from early peptide research.

 

Author BIO

Alex is a health and wellness writer covering rehabilitation, movement, exercise recovery, and evidence-informed approaches to physical well-being. His work focuses on translating complex health research into clear, accessible information that helps readers better understand recovery, mobility, and long-term physical health.

 

 

Please also review AIHCP’s Holistic Nursing Certification program and Nurse Courses see if it meets your academic and professional goals.  These programs are online and independent study and open to qualified professionals seeking a four year certification

Millions of Americans Struggle with Addiction So Here Is How Men Can Rebuild Their Lives in Recovery

Posted on by Joseph Gerard

Group psychotherapy for men with different problems and issuesWritten by Angela Rivera,

Getting through treatment is a major achievement. But if you’ve left a treatment program and are now thinking, “Okay, now what?”, you already understand the part that often gets far less attention: how to actually rebuild your life.

The need for actionable post-treatment support is enormous. According to the National Survey on Drug Use and Health, 44.6 million Americans had a substance use disorder in the previous year. That included 25.7 million people with alcohol use disorder and 26 million with a drug use disorder. About 7.1 million had both.

For men, it’s even harder. Men not only experience higher rates of several forms of substance use, but they are statistically more likely to end up in emergency departments or suffer fatal overdoses than women. Cultural expectations play a big role here, too. A man who has spent decades hearing that he should handle problems himself may find it especially difficult to admit that he needs help.

The good news is that recovery restores what addiction tends to take away: the ability to make deliberate choices about your time, health, relationships, work, and ultimately your future. You do not need to rebuild everything simultaneously, though. All you need is a practical place to start.

Treatment Ends But Recovery Keeps Going

The first weeks after treatment can be surprisingly uncomfortable. But understand one thing: this is normal and, in fact, to be expected.

Your schedule changes, you may sleep badly, and your appetite may be different. On top of that, you may have medical appointments, therapy, medication management, or lingering withdrawal-related symptoms to deal with. Then there are the less obvious problems: boredom, strained relationships, financial trouble, unemployment, and the sudden realization that a lot of your free time used to revolve around using.

None of these things mean that the treatment failed. They simply mean that treatment and long-term recovery solve different problems.

A person with opioid use disorder, for instance, may need ongoing medication treatment and monitoring after residential care. And someone recovering from alcohol use disorder may need continued counseling, medication, mutual-support groups, or some combination of these.

This is why your aftercare plan should come from your clinical team rather than a generic recovery checklist. Medication needs, mental health symptoms, sleep problems, and other medical concerns shouldn’t really be treated with a “wait and see” approach. They deserve professional attention.

Build a Day You Can Actually Repeat

How to make early recovery easier? Set a few daily goals you aim to hit every day.

For example, wake up at roughly the same time, eat regular meals, and take medications as prescribed. Go to work, school, treatment, or another productive activity. Exercise if you can, and attend your recovery support.

If this sounds too boring or simple, good. Boring routines have an advantage: they still work on a bad Tuesday.

Here’s another useful approach: create a “minimum day” for periods when motivation disappears. Meaning, decide in advance what you will do no matter how you feel.

That might mean getting out of bed, showering, eating breakfast, going to work, contacting your support person, and attending your scheduled meeting. This is flexible and personal, as some things may be more important to you than to others.

Get Specific About Stress

“Manage stress” may be reasonable advice, but it’s almost completely useless unless you define what stress looks like for you. So do that: what stresses you out the most?

Here are questions worth answering:

  • Do you become quick to anger?
  • Do you stop replying to texts and isolate yourself?
  • Do you start thinking about reaching out to old contacts?

Once you have your answer(s), map out your patterns using this sequence: Trigger → Warning Sign → Response

For example:

  • Argument with your partner → urge to leave and use → call your sponsor or therapist before leaving.
  • Paycheck arrives → thoughts about buying drugs → move money into essential expenses immediately.
  • Difficult day at work → isolation and irritability → eat, walk, shower, then contact someone.
  • Friday night → boredom and old drinking routines → make plans before Friday arrives.

The goal is to recognize your own early warning signs. That way, you have more room to respond before a craving becomes a crisis.

Your Living Environment Matters Greatly

What happens if you complete treatment and return to an “unsafe” environment? A place where people drink heavily, or drugs are readily available, or where everyone expects you to behave exactly as you did before. Yes, you are technically sober, but your environment is not helping you remain sober.

This is why recovery housing can make sense for many men. It’s a structured living environment that not only promotes sobriety but usually also independent growth, too, making it particularly valuable for early recovery.

If you’ve been Googling what is sober living, you probably have a good reason to consider it. There are many options, but Design for Recovery, for example, operates men’s sober living programs built around structure, peer accountability, and practical independence. Its programs include house meetings, recovery meetings, employment support, life-skills development, and a 12-Step foundation.

It’s not the same thing as detox or residential clinical treatment, though. A sober living home should not be treated as a substitute for medical or psychiatric care when those services are needed. The distinction is important when you are choosing a program because you want to know exactly what the residence provides and what it does not.

So if you’re seriously considering it, ask specific questions regarding:

  • House rules,
  • Drug and alcohol testing,
  • Meetings,
  • Medication policies,
  • Staff availability,
  • Relapse procedures,
  • Employment expectations,
  • How residents transition toward independent living.

Rebuild Your Independence in Pieces

After addiction, “get your life together” can sound like a ridiculous assignment (because it is). But here’s how you can make it work: break it down.

Work

If you already have a job, simply focus on keeping it while you stabilize your recovery. If you have been unemployed, update your résumé and apply for a manageable number of positions each week.

Keep in mind, employment is not only about income. A job can give your week structure, restore confidence, and reconnect you with a sense of responsibility.

Money

List your fixed expenses, debts, income, and immediate obligations. Pay essential bills first. But avoid trying to erase every financial mistake at once. A simple budget that you actually follow will always be better than an ambitious spreadsheet that lasts four days.

There are also recovery programs that provide financial coaching. Look for one that helps with the basics of budgeting, debt planning, credit education, and preparation for financial independence as part of its support.

Relationships

Do not demand instant forgiveness from people you hurt while using. You can apologize and make amends where appropriate. But trust usually comes from repeated behavior, not a particularly convincing conversation.

So, give people time to see that your actions have changed. You also have permission to create distance from relationships that still revolve around substance use, even if those relationships have existed for years.

Do Not Try to Replace Addiction With Isolation

Some men respond to recovery by going completely inward. They stop seeing old friends, which can be sensible. But then they stop seeing almost everyone, which creates another problem.

Peer support can provide something family members and clinicians cannot always provide: contact with people who understand the practical reality of staying sober. SAMHSA identifies peer support as a recovery resource for a reason: it can help people stay engaged, build skills, and connect with community.

You don’t need twenty new friends. Start with two or three people you can contact when things are going badly.

And make the relationship reciprocal. Listen to other people. Show up when you say you will. Help with ordinary things. Recovery communities become useful partly because people stop being isolated individuals and start becoming dependable members of a group.

Take Care of the Physical Basics

Sleep, nutrition, movement, and medical care are not side projects. They’re essentials.

Substance use often coexists with untreated medical conditions, poor nutrition, dental problems, poor sleep, and mental health concerns. That’s why medical attention is important: your primary care clinician and/or behavioral health providers can help determine what needs attention rather than leaving you to guess.

Exercise is especially important. It can help create structure and improve overall health, but you do not need to turn yourself into a fitness fanatic. A daily walk counts, and so does lifting weights a few times a week if that is something you enjoy.

A Practical First-90-Day Plan

If you need something more concrete, start here.

Weeks 1–2: Stabilize

Follow your discharge and medication plan. Keep appointments. Fix your sleep schedule as much as possible. Remove alcohol and drugs from your immediate environment. Tell at least one trusted person what support you need.

Weeks 3–6: Add responsibility

Return to work or school if you can. Establish a regular exercise routine. Attend recovery meetings or other support consistently. Start addressing debts, paperwork, transportation, and other neglected practical problems.

Weeks 7–12: Expand your life

Strengthen sober friendships. Take on more responsibility at work or home. Revisit longer-term education or career goals. Start planning what independent living will look like if you are in structured housing.

Importantly, know that the timeline is flexible. If your clinical team recommends a slower pace, follow that plan.

Recovery Has to Become a Life, Not Just an Absence

Addiction can consume an enormous amount of time and attention. Once that space opens up, you have to decide what goes there.

Work. Friends. Family. Exercise. Education. More money in your bank account. A clean apartment. A weekend you remember. Plans for next year. In short, ordinary but ultimately fulfilling things. Which is why they matter.

If you take anything from this piece, take this: you do not have to become a completely different person to recover; you just need to develop routines, relationships, and coping skills that make substance use less central to your life. For some men, that happens with outpatient care and a strong support network. For others, a structured sober living environment provides the extra accountability needed to make the transition.

Either way, the work continues after treatment. And that is not a bad thing. Treatment can help you stop the cycle, but recovery gives you the chance to decide what comes next.

References

  1. Substance Abuse and Mental Health Services Administration (SAMHSA). 2025 National Survey on Drug Use and Health (NSDUH).
  2. SAMHSA — 2025 National Survey on Drug Use and Health
  3. National Institute on Drug Abuse (NIDA). Sex and Gender Differences in Substance Use.
  4. NIDA — Sex and Gender Differences in Substance Use
  5. Design for Recovery. Sober Living Programs.
  6. Design for Recovery — Sober Living Programs
  7. Substance Abuse and Mental Health Services Administration (SAMHSA). Peer Support Workers for Those in Recovery.
  8. SAMHSA — Peer Support Workers

 Author Bio

Angela Rivera is a health writer who specializes in addiction care, telehealth, and behavioral science. With a background in patient education and evidence based communication, they focus on making complex clinical topics clear and approachable. Their work highlights practical strategies people can use to navigate recovery with confidence and support.

 

 

Please also review AIHCP’s Substance Abuse Practitioner Program and  CE courses to see if it meets your academic and professional goals.

5 Scenarios That May Point to an Occupational Health Concern  

Posted on by Joseph Gerard

Occupational Health written on the roadWritten by Deepika,

A patient’s symptoms often play tricks in a way that they act as footprints that don’t necessarily lead back to their origin. In other words, you may know that something has happened, but not where it all began. 

Occupation-related illnesses, although on the rise, are difficult to diagnose. A few reasons include: 

  • Similarities in clinical presentation 
  • Long latency periods between exposure and symptom onset 
  • Multifactorial etiology of chronic diseases 
  • Under-reporting of occupational conditions 

Despite the challenges, the scale of concerns makes it important to incorporate workplace cause-related health screenings. In 2024, 2.5 million non-fatal workplace injuries and illnesses were reported in the US private sector. Healthcare and social assistance recorded 3.4 cases per 100 full-time equivalent workers. 

How to tell if a patient’s workplace deserves a closer look? This article will discuss five distinct scenarios that point towards a workplace cause. 

 

Symptoms Improve During Time Away From Work 

In many cases, a patient’s symptoms have become such an ingrained part of their daily lives that they don’t see anything unusual. Even if the symptoms are recurring, they may not be able to connect them to their workplace. 

One important clue can be what happens when the patient is away from work. Say, coughing, wheezing, headaches, and skin irritation get better during weekends, vacations, or extended time away from work. The same return as soon as the patient resumes their work. 

The above-mentioned pattern calls for a closer look. NIOSH specifically recommends asking patients whether and how their symptoms change after a while away from work. A review of 2,050 physician charts at a large teaching hospital found that occupation was mentioned in only 28% of patient records. 

This is not surprising since it is easy to miss a relevant workplace clue during a clinical evaluation. Hence, the timing adds a worthwhile dimension to the patient’s history. As a healthcare professional, look for the following patterns: 

  • Symptoms getting worse during the work week and easing on weekends 
  • Feeling better during vacations or extended leave
  • Symptoms returning after resuming work 
  • Health issues worsening after a particular shift, task, or workday 
  • Palpable changes after moving to a different work area or performing different duties 

If there is a workplace exposure involved, it doesn’t always have to be obvious. NIOSH also recommends asking patients about new materials or activities introduced at work. Symptoms can fluctuate for many reasons, but a pattern gives it away. 

What to Do 

  • Compare the patient’s work days with their days off. 
  • Pinpoint the timing of the symptoms and their improvement. 
  • Ask directly about any workplace exposures. 

 

Multiple Coworkers Develop Similar Symptoms 

A workplace cause gets more difficult to ignore when multiple people develop similar symptoms. This is especially true if they belong to the same department, work area, or job role. 

The symptoms themselves do not have to be identical. Again, what matters here is the pattern. So, if several people working in the same environment begin experiencing similar issues around the same period, that’s a major sign. 

A 2025 CBS News report illustrated this pattern among Pasadena firefighters who battled the infamous Eaton fire. Captain Dave Marquez from the Pasadena Fire Department said, “For many of us, it was the worst exposure of our careers. Everybody shared similar symptoms.”

The crew had fought the fire for a brutally long 36 hours, and later submitted blood and urine samples to test for toxins. While every similar symptom may not point towards the same cause, a cluster does become good cause for questioning. Useful clues may include the following: 

  • Workers from the same area developing comparable problems 
  • Symptoms appearing after a shared workplace event or change 
  • Employees with similar duties experiencing similar complaints 
  • Unmistakable differences between affected and unaffected workers from different areas 

What to Do 

  • Ask the patient whether their coworkers share similar symptoms. 
  • Note the department, location, shift, or duties shared by the affected workers. 
  • Find out if the symptoms appeared after a specific event or change. 
  • Explore common exposure to dust, smoke, chemicals, equipment, etc. 
  • Record the patient’s account of the cluster and any workplace factors that make further evaluation necessary. 

 

Symptoms Start After a Workplace Change 

If a new symptom appears soon after the patient has shifted their workplace, then that may also serve as an important clue. Such a change may be obvious, such as introducing a new chemical or a piece of equipment. 

On the other hand, it may be a lot more subtle, such as moving to a different work area or changing shifts. The timing matters because it provides healthcare professionals with a specific point to investigate. Common workplace changes worth noting include: 

  • A new chemical, cleaning product, or material being introduced 
  • New machinery or equipment that produces dust, fumes, noise, or heat 
  • A change in work location, ventilation, or indoor conditions 
  • A change in schedule that alters sleep, meals, or recovery time 

Questions in this regard fall within the scope of occupational and environmental health. This branch of study examines how workplace and environmental conditions can influence health. So, those who pursue an occupational and environmental health degree focus beyond the symptoms to understanding exposures and assessing risks. 

Tulane University notes that the curriculum integrates public health principles with analytical methods in chemistry and statistics. Hence, the main focus areas are risk assessment, regulatory compliance, and exposure control. It makes sense since an understanding of the associated risk requires a more systematic assessment. 

What to Do 

  • Try finding out what exactly changed and when it occurred. 
  • Compare the timeline of the workplace change with the onset of symptoms. 
  • Ask what the patient was exposed to in the new environment. 
  • Determine whether symptoms vary with particular duties, location, or shifts. 
  • Document the suspected connection and see if further evaluation is necessary. 

 

A Known Workplace Hazard is Part of the Patient History 

Sometimes, the workplace connection is easier to recognize because the patient has a known exposure as part of their job. This may take the form of regular contact with chemicals, dust, fumes, biological materials, excessive heat, or radiation. 

In a 2025 field-based study, 58 construction workers in Central Florida were followed during a work shift. Then, their symptoms, hydration, and kidney function were assessed. Researchers found that 42% reported at least one heat-related illness symptom, 78% were dehydrated after the shift, and 38% showed evidence of acute kidney injury. 

It’s important to remember that a known workplace hazard is not always the cause behind a patient’s illness. However, when the patient regularly encounters a hazard that could affect their health, that exposure is a specific clinical clue worth investigating. Such a connection is especially important when: 

  • The patient regularly faces a known risk as part of their job. 
  • Symptoms appear mainly during and after the exposure. 
  • The patient has recently started working with a new substance, material, or process. 
  • The intensity or duration of exposure has increased, such as longer shifts or more time in a hot environment. 
  • Workplace protections have changed, including ventilation, hydration practices, etc. 

What to Do 

  • Ask exactly what the patient encounters at work, whether it be heat, chemicals, dust, noise, or another hazard. 
  • Find out how often or how long the conditions last. 
  • Consider whether the hazard affects the patient through breathing, skin contact, heat stress, or another route. 
  • Discuss ventilation, protective equipment, hydration, rest periods, and other controls relevant to the hazard. 
  • Think of further evaluation if the exposure and clinical presentation appear to be connected. 

 

The Condition is Unusual for the Patient’s Age or Circumstances 

It’s possible for a patient’s age, health history, or circumstances to not fit the condition that’s being evaluated. This is the case when a problem appears earlier than expected or has no clear, verifiable explanation. That’s when it’s time to look beyond the most common causes into the patient’s workplace environment. 

In a 2025 AP News report, this connection became a lot clearer. A Nevada dairy worker became infected with a newly identified strain of H5N1 bird flu after exposure at a cattle farm. The illness was mild, with redness in the eye and irritation as its main symptoms. 

However, the patient’s work with cattle provided an important part of their exposure history. The news report stated that at least 68 people in the US had been infected with bird flu the preceding year, with all but a small number having worked closely with cows or poultry. 

The example shows why an unusual condition or presentation may prompt a wider occupational history. As a healthcare professional, you may want to look more thoughtfully when: 

  • A condition appears unusually early for a patient’s age. 
  • The patient has few to no risk factors associated with the condition. 
  • The symptoms or diagnosis are unexpected given the patient’s health history. 
  • The patient’s occupation involves circumstances that may contribute to the condition. 

What to Do 

  • Determine which expected causes or risk factors are present or absent. 
  • Consider the patient’s occupation, daily activities, environment, and recent changes in circumstances. 
  • Ask whether symptoms began after starting a job, changing duties, or encountering a new workplace exposure. 
  • Avoid premature conclusions, treating the workplace as one possible factor. 

 

FAQs 

What are some signs that a health condition may be work-related? 

The most commonly observable signs include symptoms improving with time away from work, multiple coworkers being affected, and a known workplace hazard. If a condition appears to be quite unusual for a patient’s age or circumstances, that is another clue. 

What workplace factors should healthcare professionals ask patients about? 

It’s important to ask about chemicals, dust, fumes, heat, noise, biological materials, ventilation, and recent workplace changes. Also, consider asking whether the patient knows anybody from their workplace with similar issues. 

What should a healthcare professional do if a workplace cause is suspected? 

The first thing to do is to establish the timeline and compare symptoms across work and non-work periods. Then, document the relevant findings and consider appropriate health evaluation. A suspected connection should guide further assessment rather than being treated as proof of causation. 

 

Workplace Clues at a Glance 

What You Notice  What to Look For 
Symptoms improve away from work.  Better on weekends or leave 
Symptoms follow a workplace change.  New task, material, equipment, or location 
Coworkers have similar symptoms.  Shared duties, area, or exposure 
A known workplace hazard is present.  Heat, dust, fumes, chemicals, or noise 
The condition seems unusual.  Early onset or unexplained presentation 
Key questions to ask  Timing, tasks, exposures, and coworkers 
Clinical takeaway  Investigate patterns without assuming causation. 

As we discussed, the context surrounding the symptoms tells the whole patient story. So, when symptoms occur, whether coworkers are affected, and what conditions the patient encounters are all equally important. 

As per a 2026 study of 734 healthcare workers, workload, night shifts, and noise were all associated with occupational fatigue. Again, we see how several workplace factors can influence health at the same time. 

Next time a patient’s condition does not fully explain itself, look into their workplace conditions as well. A few thoughtful questions may reveal connections that are otherwise overlooked. 

Author Bio

Deepika has over six years of experience as a writer and editor. Passionate about words and learning, she takes an interest in a variety of niches. Her knack for turning complex ideas into relatable narratives allows her to resonate with the reader. When her pen falls silent, you can find her engrossed in a novel or getting her hands messy with fine arts. Through these, Deepika is committed to keeping her curiosity and creativity alive. 

 

References:

  1. Economics News Release. Employer-Reported Workplace Injuries and Illnesses (Annual) News Release. January 2026. US Bureau of Labor Statistics. 

https://www.bls.gov/news.release/osh.htm

  1. Saif Nadia, Socias-Morales Christina, et al. Primary Care and the Working Patient – Occupational Health Principles in Practice. October 2024. National Institute for Occupational Safety and Health. CDC. 

https://www.cdc.gov/niosh/bulletin/2024/primary-care-oh.html

  1. Tan Lanhui, Zhang Ruyi, et al. Multiple exposure sources and occupational fatigue profiles among healthcare workers: a cross-sectional latent profile analysis. 2026. Frontiers. 

https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2026.1811642/full

  1. Chicas C Roxana, et al. Acute Kidney Injury Among Florida Construction Workers: A Pilot Study. March 2025. PubMed. 

https://pubmed.ncbi.nlm.nih.gov/39706579/

 

Please also review AIHCP’s Health Care Certification program and CE courses see if it meets your academic and professional goals.  These programs are online and independent study and open to qualified professionals seeking a four year certification

Therapeutic Efficacy of Serrapeptase: Evaluating Systemic Enzyme Therapy in Modern Clinical Practice

Posted on by Joseph Gerard

Computer laptop with medical sign icon concept of telemedicine a

Written by Dr. Sarah Jenkins,

Routine clinical care of acute and chronic inflammatory diseases continues to be an integral part of everyday care. NSAIDs and corticosteroids are the traditional mainstay of pharmacological therapy and the indefinite use of these often produces an unfavorable gastrointestinal, renal and cardiovascular side effect. Thus, there is a growing demand in the medical community for discovery and validation of alternative or adjunctive anti-inflammatory modalities which may have good efficacy and better safety margins. Of the most promising of these substitutes is systemic enzyme therapy, a treatment which has been increasingly supported by empirical evidence over the past few decades.

Specific biological catalysts, or enzymes that stem from systemic enzyme therapy work on the immune system by controlling its response and promoting tissue repair, are at the center of the treatment. The clinical use of Proteolytic enzymes has proven to be quite promising in reducing edema, controlling inflammation and hastening the recovery process in both postoperative and traumatic clinical situations (Nair et al., 2022). A specific group of biocatalysts is the serrapeptase, also known as serratiopeptidase, a highly studied compound that is clinically useful.

 

The Biochemical Profile and Mechanism of Action

Serrapeptase is a very active protease enzyme which was extracted from an enterobacterium named Serratia marcescens E-15 which is absent from the pathogenic group of Serratia, but present in the intestine of Bombyx mori, commonly known as the silkworm. The enzyme’s strong fibrinolytic and proteolytic activity are utilized in nature by the silkworm in order to break down the tough protective cocoon of the silkworm.

In human physiology, serrapeptase acts by several different, but complementary, biochemical pathways. In fact, it has a strong anti-edemic effect which reduces the swelling of tissues. Serrapeptase helps remove abnormal exudates and denatured proteins, that often build up in localized areas of tissue damage. Serrapeptase can effectively inhibit the inflammatory cascade’s key chemical mediators of inflammation such as bradykinin, histamine and serotonin, which in turn has a beneficial effect on vascular permeability and the localized edema that can occur as a result of the inflammatory process.

Secondly, serrapeptase has a very high fibrinolytic activity. Actively breaks down dead/failing tissues like fibrin but does no damage to thriving/living cells. This selective proteolysis helps to remove obstruction from microcirculation at the injury site and allows better oxygen and nutrient transfer to the site which is crucial for tissue repair, enhancing the removal of metabolic waste. In addition, serrapeptase partly prevents the release of amine substances in inflammatory tissues which makes it an excellent analgesic while not having the cyclooxygenase, or COX, pathway typical of most NSAID’s.

Clinical Applications in Healthcare

Its multi-facet pharmacological properties paved the way for clinical studies and eventual application in a variety of therapeutic areas.Its pleiotropic properties are the reason why it has been the subject of clinical investigation and then applied to a variety of therapeutic fields. Its physiological functions can be adapted and utilized by healthcare practitioners in their practice for optimal patient outcomes.

Otolaryngology and ENT

Chronic inflammation can cause excessive production of thick, viscous mucus leading to excessive chronic sinusitis, rhinitis and bronchitis in the field of otorhinolaryngology. Serrapeptase has been shown to be effective in changing the viscoelasticity of sputum and nasal secretors in clinical evaluations. Mucin is a macromolecule that its viscosity is reduced by the enzyme which allows the expectoration of larger amounts for mucociliary clearance (Mazzone et al., 1990). Thus it is an important adjunctive treatment for respiratory diseases that involve heavy secretion of mucus.

Oral and Maxillofacial Surgery

Edema and pain after surgery are a big problem in maxillofacial surgery, especially after surgical removal of impacted mandibular third molars. These cases have been subjected to a double-blind and placebo controlled clinical test of the prophylactic use of serrapeptase. The results are usually statistically significant and show a decrease in post-operative trismus, which is the stiffness of the jaw, swelling of the face and pain intensity when compared with placebo suggesting an effective alternative to corticosteroids for the management of surgical trauma (Al-Khateeb & Nusair, 2008).

Orthopedics and Traumatology

The rapid, successful healing of acute inflammation has been essential in musculoskeletal injuries in order to avoid chronic inflammation and functional losses. Serrapeptase is commonly used in sports medicine and orthopedics to treat sports injuries like sprains, torn ligaments and post-operative orthopedic recovery. This increases the speed of reabsorption of hematomas and reduces tissue swelling as a result of this, patients can return to normal functional status (Tiwari, 2017) to a more functional level of mobility earlier on.

The Role of Serrapeptase in Biofilm Disruption

The subject of serrapeptase in relation to infectious diseases and resistance to them is one of the most interesting and current research fields related to serrapeptase. A lot of pathogenic bacteria cope with host immune system and pharmacological treatment by forming these complex polysaccharide matrices called extracellular polymeric substances or EPS that encapsulate the bacterial communities.

Recent microbiological investigations have found serrapeptase to be a strong inhibitor of the effects of biofilms. Enzymatically breaking down the structure of the biofilm matrix, Serrapeptase removes the bacteria’s protection. The action is very important in concentrating the antibiotic effect locally and helping the action of the antibiotics in use at the time (Selan et al., 1993). The addition of targeted proteolytic enzymes is an exciting new avenue in antimicrobial stewardship for the healthcare provider treating chronic infections with organisms that routinely form biofilms. This is particularly relevant for pathogens in the respiratory tract or prosthetic implant-associated infections, such as recurrent joint infections.

Pharmacokinetics and Formulation Imperatives

Pharmacokinetics of serrapeptase need to be carefully controlled in order that the efficacy of the product can be realized. Unlike most enzymes, the enzyme serrapeptase is protein based and is spontaneously decomposed by highly acidic environment of the stomach, specifically gastric acid and pepsin. In the stomach the enzyme is denatured, so its systemic absorption in the small intestine is entirely cancelled out making the therapy without any effect.

Systemic enzyme treatment is then recommended and when so, it is medically obligatory to indicate enzyme preparations with high level enteric coating. Since the enzyme would not be affected by stomach acid, the capsules are enteric coated, releasing the enzyme along the way in the alkaline environment of the small intestine where it is then absorbed into the systemic venous circulation via the intestinal lymphatic system. The provider should recommend the use of formulations which are tested rigorously, for instance, Liver Medic’s serrapeptase supplements optimised to avoid breakdown by gastric enzymes, to maximise systemic bioavailability and/or to provide a constant therapeutic effect throughout treatment for maximum efficacy in clinical outcomes.

Safety Profile and Contraindications

On the whole, systemic enzymes are safe and well tolerated, but require proper clinical judgement on the part of the healthcare provider when deciding on the use of systemically acting enzymes. Some gastrointestinal upset, such as nausea or loss of appetite, is the most common side effect; this is usually mild and does not last long.

As it has fibrinolytic activity, use Serrapeptase with caution in patients with bleeding disorders or those on aggressive antiplatelet and/or anticoagulant medications that could potentially interact with Serrapeptase and increase the risk of bleeding, such as Warfarin, Clopidogrel. Two weeks before being scheduled for any surgeries, systemic enzyme therapy is routinely stopped, and sometimes reasoned.

Conclusion

By combining synthetic systemically acting enzymes, a multi-targeted treatment approach that suits today’s integrative clinical practice in the treatment of inflammation. The versatility of Serrapeptase is particularly impressive for its ability to treat all these conditions: edema, pain, mucous coat issues, and even bacterial biofilm, without experiencing the gastrointestinal or renal side effects as with extended use of NSAID’s. With ongoing research and investigation of these biocatalysts’ vast biochemical potential, serrapeptase will most likely become an added significant treatment tool in the modern day’s ‘medical arsenal’.

References

Al-Khateeb, T. H., & Nusair, Y. (2008). The anti-inflammatory effect of a proteolytic enzyme (serrapeptase) on trismus, pain and swelling following third molar extraction of the mandible. International Journal of Oral and Maxillofacial Surgery, 37(3), 264-268. https://doi.org/10.1016/j.ijom.2007.11.011

Nair, S. R., & Sandeep, R. (2022). A systemic enzyme with pleiotropic therapeutic properties that is called Serrapeptase. Pharmacological Reports, 74, 1-14.

Tiwari, M. (2017). Serratiopeptidase – a role in the resolution of inflammation. Wang FY, Yang CP, Huang L et al (2017) Evaluation of the Stability of Roscovitina in Pharmaceutical Suspensions. Asian Journal of Pharmaceutical & Clinical Research 10(5): 221-224.

Author Bio:

Sarah Jenkins Ph.D. is an independent Clinical Researcher, Medical Writer with special interests in Integrative Pharmacology and Advanced Anti-inflammatory Therapies. She has written and peer-reviewed papers and courses on the positive evidence and support from very holistic modalities offering helpful optimization strategies on managing chronic disease and Post Surgery improvements and regimens in healthcare professionals.

 

When a Contaminated Patient Reaches the ER: Is Your Team Ready?

Posted on by Joseph Gerard

Female nurse with a mask putting on glovesWritten by Ryan Harris

A man walks into the emergency department after an accident at a nearby plant. He’s coughing, his shirt is wet, and two coworkers drove him in because waiting for an ambulance felt unnecessary. At triage, nobody yet knows what he was exposed to.

That’s a different problem from treating the cough.

A contaminated patient can bring the incident through the hospital doors with them. Clothing, shoes, hair, a wheelchair, a phone, or the hands of a well-meaning staff member can move a hazardous substance into spaces that were never meant to be part of the response. The clinical team may be excellent at stabilizing a sick patient and still be unprepared for the exposure-control problem arriving with that patient.

The first mistake happens before anyone reaches a shower

Hospitals sometimes picture hazardous-material response as something that happens at the scene: firefighters in protective suits, a taped perimeter, a HAZMAT unit, then a clean patient delivered to the ED. That sequence is convenient when it happens. Patients can also self-transport, leave a scene before decontamination, or arrive with incomplete information about what occurred.

The training question gets muddled because “HAZWOPER” is often treated as if it means one standard course. Staff designated to deal with contaminated patients need training that matches the job they’re expected to perform, while the broader HAZWOPER training framework varies according to duties, exposure and type of work. A nurse assigned to decontamination, a security officer controlling access, and a registration clerk who first notices an unannounced contaminated patient don’t have identical responsibilities.

OSHA’s HAZWOPER guidance for hospital staff gets more specific. Personnel expected to provide limited decontamination so a patient can receive medical care must be trained to the First Responder Operations Level, with particular attention to PPE and decontamination procedures. OSHA also requires annual refresher training or a demonstration that those competencies are being maintained.

For a department manager, the useful question is simple: who is expected to touch the patient before decontamination is complete? Write down the actual positions, including nights and weekends. If the answer depends on whoever happens to be available, the plan is relying on improvisation.

The ER door is a boundary, not just an entrance

Once contamination is suspected, space matters. In many setups, that zone ends around the emergency department door, separating areas where contamination may still be present from spaces expected to remain clean.

That boundary can disappear quickly. An ambulatory patient walks inside because nobody stops him. A family member follows. A tech rolls out a wheelchair and brings it back through the same doors. Someone carries the patient’s bag to registration to find an insurance card. None of those actions looks especially dangerous in the moment.

Healthcare workers already operate around a wide range of occupational health hazards in nursing, including infectious exposures and physical strain. Chemical contamination changes the calculation because normal clinical habits can spread the hazard. Moving straight toward a distressed patient may be instinctive, while the safer first action could be stopping their movement and bringing trained, properly protected staff to them.

A prepared department handles this through small operational details. Staff know which entrance is used for decontamination. Security knows which doors need to stay controlled. Clean equipment doesn’t drift into the contaminated area without a plan for getting it back out. The route from decontamination to treatment is established before someone has to improvise around parked stretchers and waiting families.

A written plan can still fail on a Tuesday afternoon

Most hospitals can produce an emergency plan. The harder test is whether it survives an ordinary shift with ordinary staffing.

Imagine a contaminated patient arrives at 2:15 p.m. The charge nurse is covering a staffing gap. One member of the decon team is at lunch and another transferred units three months ago. Respiratory-protection equipment is stored where newer staff have never seen it. Security knows where the decon area is but not who has authority to activate it. Registration encounters the patient first.

A useful plan assigns those decisions before the event. Who activates the response? Who establishes the contaminated area? Who brings out PPE? Who keeps patients and visitors away? Who contacts outside responders or poison-control resources when the substance is unclear? Who handles contaminated clothes, phones and wallets? Who decides when the patient can cross into the clean treatment area?

Those questions are familiar in broader emergency management, where hazard vulnerability analysis and incident command systems are used to establish responsibilities before people are making decisions under pressure. A small chemical exposure doesn’t need a sprawling command structure, but it does need one understood chain of responsibility.

Drills are good at finding things a binder won’t. A hose connection turns out to be behind a locked panel. A staff member can don respiratory protection but can’t communicate clearly while wearing it. The stretcher intended for non-ambulatory decontamination doesn’t fit where the plan says it will. Someone realizes nobody has decided how to manage a contaminated family member who arrived in the same car.

There’s a human side as well. Patients may be frightened, confused, reluctant to remove clothing, or worried about coworkers still at the scene. The calm, practical approach used in crisis intervention is useful when staff need cooperation without adding more distress. Clear instructions matter when someone is being asked to undress, surrender personal belongings or wait outside the normal treatment path.

Decontamination is a workflow, not a shower

Water is only one part of decontamination. The steps before and after washing determine whether the substance stays contained.

Speed still matters. CDC guidance for chemical emergencies advises exposed people to get the chemical off the body as quickly as possible and, when possible, undress and shower ideally within the first 10 minutes. In an ED, that urgency has to coexist with airway problems, trauma, limited mobility, hypothermia risk, privacy, staff protection and the possibility that nobody yet knows exactly what the substance is.

A walking patient who can follow directions presents one workflow. A confused patient on a stretcher presents another. The second puts staff closer to contaminated clothing and skin for longer while they’re also trying to move, support, turn and stabilize the person.

Clothing deserves more attention than it usually gets. Pulling a contaminated shirt over someone’s head can move material toward the face and hair. Cutting it away may reduce that spread. Once clothing and belongings are removed, they need controlled handling rather than being left beside the shower or handed back to a family member.

The handoff into the ED matters just as much. “Washed” can’t be the only criterion for crossing into a clean area. Teams need a shared endpoint based on hospital procedures, the suspected material, the patient’s condition and whatever technical guidance is available. Otherwise, uncertainty simply moves from the decon area into the treatment space.

Afterward, there’s still contaminated equipment, waste, staff doffing, possible employee exposure, documentation, cleanup and restocking to deal with. A response that effectively ends when the patient reaches a clean bed leaves those problems for somebody else on the shift.

Wrap-up takeaway

A contaminated patient tests clinical care and worker protection at the same time. The hospital can’t assume that firefighters, EMS or the scene response will remove every hazard before someone reaches the front door. Readiness depends on knowing who may encounter contamination, what those people are prepared to do, where the contaminated area begins and ends, and how the patient moves into clean treatment without bringing the exposure along. The weak points are often ordinary: an outdated roster, equipment nobody has practiced with, an uncontrolled entrance, or a responsibility assigned vaguely to “staff.” Those are fixable before the pager goes off. Today, pull out the emergency plan and ask the charge nurse on duty one question: if a chemically contaminated walk-in reached the front door right now, who would take the first three actions?

Author bio:

Ryan Harris is a writer covering education, workplace learning, and practical safety topics. His work focuses on turning technical guidance into clear, useful information, with an emphasis on training, preparedness, and the real-world decisions professionals face on the job.

 

Please also review AIHCP’s Nursing Management Certification program and CE courses see if it meets your academic and professional goals.  These programs are online and independent study and open to qualified professionals seeking a four year certification

How Case Managers Connect the Pieces of Fragmented Healthcare 

Posted on by Joseph Gerard

African American medic shows medical test results on digital tablet computer to another doctor. Multicultural doctors discuss ways of treatment in middle of hospital corridor. Medical staff at work.Written by Deepika

No matter how diligently providers play their part, suboptimal care is a known outcome of a fragmented healthcare system. Consider the following scenario that is still commonplace: A patient is discharged with a new medication, a specialist referral, and follow-up instructions with primary care. 

The primary care provider receives part of the discharge information. At the same time, the specialist is working from a different set of records. Meanwhile, the patient is managing a chronic condition through another clinic, waiting for a referral appointment that has not been scheduled. 

Each provider is doing what they can, but nobody has the complete picture. This kind of fragmentation only becomes more complex when patients must navigate multiple parts of the healthcare system. 

In 2025, nearly 12.5 million people across the US were enrolled in both Medicare and Medicaid. Again, the two programs operate separately, with different eligibility requirements, benefits, and payment structures. The issue is ensuring that each provider has a shared understanding. 

Case managers can help create a connected process, and this article will explore how. 

 

Tracing Gaps in a Patient’s Care 

Before the fragmented pieces are connected, case managers need to know where those pieces are falling short. This means they would look beyond the immediate reason, be it a referral or recent hospitalization. Essentially, a patient’s larger care landscape would be assessed. 

If we go by recent research, a lot can be uncovered when care is examined across transitions. Take the example of a 2026 study involving 2,426 adults in a pharmacy-driven care transition program. It was discovered that 81.7% of the cases involved at least one medication error. 

Moreover, non-adherence to medication was noted in 45.6% of patients, along with barriers to accessing medication in 12.7% of cases. If a case manager were to fixate their judgment on a single encounter/record, they would not understand the real needs of the patient. 

A broader assessment would bring together information from medical records, the care team, and the patient. On a case-to-case basis, it’s important to look at the following:

  • Incomplete referrals: A recommended specialist or service has not been scheduled or received. 
  • Gaps in follow-ups: Instructions from one care setting have not been carried through to the next. 
  • Medication discrepancies: Medication lists, dosages, or treatment instructions that differ between providers. 
  • Duplicate services: Tests, assessments, or services may be recurring because providers lack visibility into what has already occurred. 
  • Unaddressed barriers: Transportation, cost, access, or other practical issues may make an otherwise relevant care plan challenging to follow. 
  • Missing information: Relevant records, test results, or treatment updates have not reached the provider who needs them. 

A September 2026 report by the American Medical Association on Ochsner Health’s hospital-to-home programs makes the practical importance of identifying such gaps much clearer. Ochsner had 293 patients with congestive heart failure enrolled in its acute care at home program in 2025. 

Although they represented 15% of the program’s home patients, they accounted for 16% of all reutilizations. In response, one of Ochsner’s strategic priorities for 2026 is to improve care coordination for this group. As Dr. Beau Raymond, the Chief Medical Officer for population health at Ochsner, stated, “We needed to be smarter about simple care coordination activities.” 

Also, keep in mind that Ochsner’s approach was not just about analyzing clinical information. It included identifying patients at risk, determining which home-based program fits their needs, and helping case managers navigate available options. Instead of documenting every detail of a patient’s journey, case managers should determine where the care pathway is most likely to break down. 

 

Building Bridges Across Providers and Care Settings 

After the gaps in a patient’s care have been identified, the next challenge is bringing the right people and services into the same care pathway. A case manager may have to coordinate communication between a primary care provider, specialist, hospital team, home health service, or a community-based resource. 

Each of these roles may differ, but that should not prevent the patient’s care from moving forward. The complexity of this coordination can vary depending on where and how a patient receives care. 

For instance, Community CareLink notes that distance and staffing make coordination critical in rural communities. Patients may have fewer healthcare providers nearby, requiring them to travel beyond their local community for certain services. 

The Health Resources and Services Administration (HRSA) notes that only 2% of residency training occurs in rural areas. Strengthening rural training will improve access to care and increase the likelihood that physicians practice in these communities. 

For rural health transformation, this can mean coordinating care that extends beyond its immediate network. A case manager may need to connect a patient with an outside specialist, help address scheduling barriers, and ensure the referring provider has all the necessary information. 

Essentially, several practical responsibilities form a part of this bridge-building process. These include the following:

  • Making sure each member of the care team has clear responsibilities 
  • Facilitating communication between professionals working from separate records 
  • Helping move a referral beyond the initial order by checking whether the patient reached the appropriate service 
  • Carrying relevant information and care responsibilities across settings such as hospitals, outpatient clinics, and community services 
  • Incorporating practical support, social services, and other community-based assistance into the broader care plan 

 

Turning Coordination Into Continuity of Care 

Connecting providers is only half of the work done. A patient can still experience a breakdown in their care if they do not receive a follow-up on the next steps. Continuity of care depends on whether the plan still works after those initial connections have been made. 

In other words, the focus of case management here is to keep the connected pieces together. Case managers can monitor whether recommended services were accessed, whether treatment plans are being followed, and whether new barriers have emerged. They also have the chance to analyze the patient’s needs amid changing circumstances. 

According to a recent CBS News feature, continuity of care becomes more difficult when local healthcare resources change. Sturgis Hospital in rural Michigan closed on June 19th, ending services that included surgery, medical imaging, physical therapy, and cardiac rehabilitation. 

The loss of its emergency department also meant that some patients who previously took an approximately 2-mile ambulance ride would now have to travel 25 miles. Situations like this show why continuity requires more than maintaining a list of referrals. Since a facility is no longer available, the patient’s care pathway may have to be rebuilt around what is accessible. 

Case managers play a significant role in that rebuilding process. Maintaining continuity of care may involve the following:

  • Confirming that referrals, appointments, and treatments happened promptly 
  • Watching for changes in the patient’s condition, circumstances, and ability to manage their care plan 
  • Adjusting coordination when a patient’s health or support needs change 
  • Ensuring important updates and responsibilities move with the patient from one stage of care to the next 

The Sturgis example also shows why continuity cannot be treated as a one-time task. The report noted that other clinics remained available after the hospital closed, but the emergency department’s absence left facilities in Three Rivers, Coldwater, and LaGrange, Indiana, as the closest alternatives to patients. 

A case manager can become a crucial link in such fragmentation. Instead of directing a patient to a new provider, they can look through the care plan again to see what has changed. That’s how it’s possible to ensure the next set of services still fit together. This type of attention to detail is particularly relevant in cases where the patient has multiple conditions or practical barriers to overcome. 

 

FAQs 

What problems do case managers help address in fragmented healthcare?

Case managers help identify gaps such as incomplete referrals, medication discrepancies, duplicate services, and practical barriers. They bring together information from different providers and settings to determine whether a patient’s care pathway is breaking down. 

How do case managers improve coordination between healthcare providers?

The way case managers improve coordination is by connecting care providers, facilitating information sharing, and helping carry care plans across different settings. This can be especially important when patients must travel for services or receive care from multiple organizations that do not work together. 

How do case managers help maintain continuity of care?

Case managers follow up after referrals and transitions, monitor changing needs, and adjust care coordination when circumstances change. If a provider or service becomes unavailable, they can help identify alternatives to ensure important information moves with the patient. 

 

Fragmented Healthcare At a Glance 

Care Challenge  Case Management Insight 
Scattered information  Find the missing pieces. 
Incomplete referrals  Follow the referral through.
Conflicting medication records  Reconcile the differences. 
Disconnected providers  Keep communication going.
Care across distant settings  Bridge the gaps between services.
Changing patient needs  Reassess the needs and adapt the care plan accordingly.
Loss of local services  Rebuild the care pathway. 
One-time coordination  Keep care connected.

Fragmentation in healthcare cannot be attributed to a single person or one failed interaction. It can develop when information is scattered across records and referrals lose their momentum. 

Case managers have the unique potential to make the system more connected. A 2026 randomized controlled trial involving 1,387 adults with multiple chronic conditions compared three approaches to case management after hospital discharge. 

While no considerable difference was observed in 90-day readmission rates, in-person care enabled patients to better understand and manage their care over the following year. Successful coordination cannot be determined by a single outcome. To keep a patient’s journey connected over time, multiple factors must be considered and addressed.

Author Bio

Deepika has over six years of experience as a writer and editor. Passionate about words and learning, she takes an interest in a variety of niches. Her knack for turning complex ideas into relatable narratives allows her to resonate with the reader. 

When her pen falls silent, you can find her engrossed in a novel or getting her hands messy with fine arts. Through these, Deepika is committed to keeping her curiosity and creativity alive. 

References:

  1. Centers for Medicare & Medicaid Services. July 2026. Medicare-Medicaid Coordination Office Fiscal Year 2025. 

https://www.cms.gov/files/document/mmco-report-congress.pdf-2

  1. Kevin McKeough. Better handoffs help home care cut hospital readmissions. American Medical Association. 

https://www.ama-assn.org/practice-management/payment-delivery-models/better-handoffs-help-home-care-cut-hospital

  1. Williams Kelly, et al. April 2026. Integrated care for chronic conditions: a randomized care management trial. PubMed. 

https://pubmed.ncbi.nlm.nih.gov/41838981/

  1. Rural Residency Planning and Development (RRPD) Program. September 2026. Health Resources & Services Administration. 

https://www.hrsa.gov/rural-health/grants/rural-health-research-policy/rrpd

 

 

Please also review AIHCP’s Case Management Certification program and our CE courses as well, to see if they meet your academic and professional goals.  These programs are online and independent study and open to qualified professionals seeking a four year certification

What Clinicians Should Ask Patients About Herbal Supplements

Posted on by Joseph Gerard

Holistic Wellness Advice: What does Berberine do for you?Written by Dr. Galina Kosyak,

Patients rarely file herbal products under “medication”, so they rarely mention them. For anyone doing medication reconciliation or patient education, that silence is a practical problem: herbal products are pharmacologically active, and several carry well-characterised interactions. Here is how to ask, what to ask about, and why the label limits what you can assess.
Ask a patient what medications they take and you will usually get a reasonable list. Ask what else they take and the list often grows – a turmeric capsule every morning, something for sleep a friend recommended, a mushroom powder in the smoothie, an echinacea tincture kept in the cupboard for winter.

That second list rarely makes it into the chart. Not because patients are concealing anything, but because most of them do not file these products under “medication” at all. They are food. They came from a shop, not a pharmacy. Nobody wrote a prescription.

For anyone doing medication reconciliation, patient education or care coordination, that gap is a practical problem rather than a philosophical one. Herbal products are pharmacologically active. As the National Center for Complementary and Integrative Health puts it plainly in its clinician guidance, herbal products carry the same dangers as other pharmacologically active compounds, even though the public tends to assume otherwise.

Why the question usually fails

The standard phrasing does most of the damage. “Are you taking any other medications?” invites a patient to mentally exclude anything sold in the vitamin aisle. “Any supplements?” is better, though many people interpret “supplements” narrowly – a multivitamin, perhaps, but not the herbal tincture or the powdered extract.

Three reframings tend to work better in practice:

Ask about the container, not the category. “What’s in your medicine cabinet besides your prescriptions? Anything in a bottle, a capsule or a dropper?” This invites an inventory rather than a judgement about what counts.

Ask about purpose. “Is there anything you take for sleep, for energy, for joints, for digestion?” Patients who would never describe themselves as supplement users will readily describe what they take and why.

Ask them to bring the bottles. A photograph of the labels on a phone is enough. This single request resolves more ambiguity than any amount of questioning, for reasons that become clear below.

It also helps to signal that the question is clinical rather than disapproving. Patients who expect to be lectured tend to answer briefly. Patients who understand you are checking for interactions tend to be thorough.

What actually matters clinically

The literature on herb-drug interactions is uneven – a great deal of it is inferred from animal studies or cell assays rather than observed in patients. NCCIH is explicit about this, and it is worth carrying that caution into practice rather than treating every theoretical interaction as established fact.

That said, several are well enough characterized to warrant routine attention. NCCIH’s own clinician digest on herb-drug interactions highlights a short list worth knowing by name:

  • St John’s wort carries a high risk of interaction through enzyme induction, with documented effects on cyclosporine, oral contraceptives and digoxin. Of everything on the shelf, this is the one to ask about directly.
  • Ginkgo biloba increases bleeding risk in patients on warfarin, and is incompatible with efavirenz.
  • Goldenseal reduced metformin levels by roughly a quarter in an NCCIH-funded study – a relevant signal for any patient managing glucose.
  • Green tea at high doses reduces the effectiveness of nadolol and atorvastatin.
  • Asian ginseng has mixed evidence around calcium channel blockers, statins, antidepressants and warfarin.
  • Chamomile, cranberry and cat’s claw each carry plausible interactions – with oral contraceptives, warfarin and anticoagulants respectively – on thinner evidence.

The perioperative period deserves separate attention. Several widely used botanicals affect platelet function or interact with anaesthesia, which is why most surgical practices ask patients to stop herbal products one to two weeks before an operation. Patients frequently do not connect that instruction to the bottle in their kitchen, because in their mind it is not a drug. Making the instruction concrete – naming the products, not the category – improves compliance considerably.

The label problem, and why it limits what you can assess

Here is where the bottles matter. Suppose a patient reports taking “echinacea”. That word alone is close to useless clinically.

There are several species sold under that name, and they are not equivalent. The same applies across the botanical shelf: different species share a common name, and different parts of the same plant – root, leaf, aerial parts, bark – differ substantially in composition. An extract and a powdered whole herb of the same species are not interchangeable either, and the concentration ratio is frequently absent from the label altogether.

So the useful information on a supplement label is narrow and specific:

  • The botanical name. Hydrastis canadensis is goldenseal. Other species contain the same headline compound and are cheaper. Without the binomial, the identity is not guaranteed.
  • The part of the plant. Root and rhizome behave differently from aerial parts.
  • The form. Extract or whole herb, and at what ratio.
  • A lot number and date. Basic, and the quickest indication that someone is keeping records.

There is one more line worth teaching patients to read, and it is the only mandatory disclosure about the supply chain on the entire package. US labelling rules require the name and address of the manufacturer, packer or distributor – any one of the three satisfies the requirement. If the company named did not make the product, it must say so, using a qualifier such as “Distributed by” or “Manufactured for”. Nothing requires the country of manufacture to appear anywhere.

The practical consequence is that an American address on a bottle tells you where a company is, not where a product was made. A handful of manufacturers publish this detail openly; AMPEXT, a US plant-extraction company, has written a plain-English explanation of what supplement labels do and do not disclose, which is a useful thing to point patients toward when they ask how to compare products.

Documenting it

Whatever the patient reports belongs in the record in the same way a prescription would – product name, botanical name if available, dose, frequency, how long they have been taking it, and why. “Takes herbal supplements” is not documentation; it is a note that the question was asked.

Two habits make this sustainable. Re-ask at every reconciliation rather than once at intake, because supplement use is episodic and often seasonal. And record the reason alongside the product – a patient taking valerian for sleep and a patient taking valerian because a relative suggested it are different conversations when the time comes to discuss stopping.

The underlying point

None of this requires taking a position on whether herbal products are beneficial. The clinical question is narrower and more answerable: what is this patient actually ingesting, and does it interact with anything else they are taking.

That question cannot be answered if it is never asked in language the patient recognises, and it cannot be answered accurately if the answer arrives as a common plant name with no species, no plant part and no form attached.

Ask about the cabinet. Ask them to bring the bottles. Write down what the label says.

About the author

Galina Kosyak, PhD in Medical Sciences, is Medical and Scientific Advisor at AMPEXT (American Plant Extraction). A physician trained in physical medicine and rehabilitation, she earned her medical degree in 1999 and later a PhD in Medical Sciences, and spent many years as a Senior Research Scientist at the Research Institute of Medical and Social Expertise and Rehabilitation, where she conducted clinical research in rehabilitation medicine. At AMPEXT she reviews educational articles and product monographs for accuracy and balance against current evidence. Full biography and editorial policy: ampext.com/information/author-g-kosyak

Disclosure: the author is affiliated with AMPEXT, which is named in this article.

 

Please also review AIHCP’s Holistic Nursing Certification program and Nurse Courses see if it meets your academic and professional goals.  These programs are online and independent study and open to qualified professionals seeking a four year certification

What Is KPV? A Clear Look at the Peptide Studied for Inflammation, Gut, and Skin

Posted on by Joseph Gerard

Peptides under magnifying glass. Thorough analysis and inspection of peptides. Taking a closer look at peptides. Examination of the concept of peptides

Written by Biana Borchenko, FNP-BC, Nurse Practitioner,

KPV is one of the shortest peptides getting attention in wellness circles, and its size is part of the appeal. Made of just three amino acids, it is small enough to slip into cells and is studied for a single job that matters to a lot of people: calming inflammation. That focus is why interest in KPV peptide benefits has grown among readers dealing with gut and skin issues. Understanding what the research supports, and what it does not, keeps expectations realistic.

KPV is a fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), a signaling molecule your body already makes. Researchers isolated the tail end of that hormone and found it kept much of the anti-inflammatory signaling while shedding other effects. In other words, KPV is studied as a targeted messenger rather than a broad drug.

Because inflammation sits underneath so many gut and skin complaints, that targeting is what makes KPV interesting to clinicians and researchers. Physician-led practices such as Robertson Wellness & Aesthetics treat peptides like KPV as something to consider case by case, after a medical history, rather than a supplement to self-prescribe. The biology helps explain why.

How KPV is thought to work

The leading explanation is that KPV acts inside the cell to quiet inflammatory signaling, including pathways tied to the messenger NF-kB. By dialing down that signaling, it may reduce the inflammatory response in tissues like the gut lining and the skin, according to preclinical studies indexed by the U.S. National Library of Medicine.

Two features get researchers’ attention. First, KPV appears to work at low concentrations. Second, it seems to act without the pigment-related effects of the parent hormone, which is why it is studied as a focused anti-inflammatory signal rather than a tanning agent.

What the research shows, by area

Most of the evidence is preclinical, meaning cell and animal models rather than large human trials. The signals are promising enough to justify continued study, not strong enough to promise results.

Area of interest What research explores Evidence stage
Gut Support for the intestinal lining and inflammatory bowel models Preclinical
Skin Calming inflammatory skin responses and supporting repair Preclinical/early
General inflammation Reducing NF-kB-linked inflammatory signaling Preclinical

Read the table as a map of open questions, not a list of proven treatments. A compound can look encouraging in a dish or an animal model and still need years of human research before anyone can speak confidently about benefit and dose.

Who tends to look into KPV, and who should wait

In clinical conversations, KPV comes up most often with people focused on gut comfort, inflammatory skin concerns, or general inflammatory load who want medical guidance rather than gray-market products. Suitability is decided individually, not from an online checklist.

Some people should hold off unless a physician says otherwise, including anyone who is pregnant or breastfeeding, anyone managing a serious medical condition, and anyone already on medications that affect immune or inflammatory pathways. A clinician weighs those factors before anything is recommended.

Why delivery method comes up so often

KPV is discussed in several forms, including oral capsules, topical preparations, and injectable versions, and the format is not a minor detail. How a peptide is delivered affects how much reaches the target tissue and how it is handled by the body, which is one reason clinicians care about the route as much as the compound.

For gut-focused interest, an oral or targeted approach is often the talking point, while skin concerns raise questions about topical use. None of these formats is automatically “best,” and the research behind each varies. This is exactly the kind of trade-off a licensed provider can walk through based on your specific goal rather than a general recommendation online.

Three things people get wrong about KPV

A few misconceptions show up again and again, and clearing them helps set realistic expectations.

  • “It is natural, so it is risk-free.” KPV is derived from a natural hormone fragment, but the products sold are manufactured, unregulated, and not proven safe long-term.
  • “More is better.” KPV is studied at low concentrations; higher amounts are not automatically more helpful.
  • “It is proven for gut or skin conditions.” The human evidence is not there yet. Interest is based largely on preclinical work.

Keeping these straight makes it easier to read marketing claims critically and to have a grounded conversation with a clinician.

Safety and the honest unknowns

KPV is not an FDA-approved medicine, so there is no standardized dose and no quality guarantee for products sold outside a clinical setting. Short reports tend to describe it as well tolerated, but long-term human safety has not been established in large studies. Purity and accurate labeling are real concerns with self-sourced peptides.

These statements have not been evaluated by the Food and Drug Administration. KPV is not intended to diagnose, treat, cure, or prevent any disease, and is not an FDA-approved therapy. Talk with a licensed medical provider before considering any peptide.

For readers who would rather explore KPV with medical oversight than order a vial online, Robertson Wellness & Aesthetics, a physician-supervised medical spa in Beverly Hills, is one clinic that evaluates peptide options under clinical care.

 

 

Please also review AIHCP’s Holistic Nursing Certification program and Nurse Courses see if it meets your academic and professional goals.  These programs are online and independent study and open to qualified professionals seeking a four year certification

6 Doctor Quality Analytics Platforms Powering Value-Based Care in 2026

Posted on by Joseph Gerard

Stethoscope_and_keyboard_illustrating_concept_of_digital

Written by Cassandra Rosas

A doctor being “in-network” answers exactly one question: will the claim get paid. It says nothing about whether that doctor’s patients recover faster, avoid unnecessary procedures, or end up back in the emergency room three weeks later. For years, that gap didn’t matter much because nobody was measuring it at scale, but now a growing number of platforms are, and the results are reshaping how employers, health plans, and the case managers between them make referral decisions. Case managers, more than most people in the system, sit exactly at that intersection: clinically fluent enough to judge a referral, accountable enough for cost that a referral choice actually matters.

Commercial value-based arrangements grew from 34.6% of payments in 2022 to 39.2% in 2023, according to the HCP-LAN annual survey, conducted jointly with AHIP and BCBSA. That shift only works if someone can tell a high-value doctor from an average one, which is exactly the gap these six platforms are built to close. Garner Health tops this list because it’s built the furthest into that specific problem. The rest fill in adjacent pieces of the same puzzle.

What “doctor quality analytics” means for case managers

Ask 10 case managers what “in-network” means and most will describe a directory: a name, an address, a specialty code. Ask them what “high-quality” means for that same doctor and the answers get vague fast, because until recently there wasn’t much data to point to.

Doctor quality analytics platforms replace that vagueness with claims-based measurement: tracking things like complication rates, readmissions, and procedure volume at the individual physician level, then scoring providers against their peers in the same specialty and geography. For a case manager balancing a patient’s outcomes against a plan sponsor’s cost targets, that score is the difference between a referral made on convenience and one made on evidence.

This is the mechanical layer underneath the broader move toward value-based care, where a health plan gets paid, or penalized, based on outcomes rather than visit volume. You can’t manage what you can’t measure, and provider-level quality data is what makes that measurement possible below the plan level, down to the individual referral.

Consider a case manager referring a patient for a routine orthopedic procedure. Under the old model, the choice comes down to who’s in-network and who has an open slot. A quality-analytics model adds a layer: the case manager can see in advance whether one surgeon’s patients tend to need a second procedure within a year and others don’t. That’s the kind of signal that used to live only in a hospital’s internal peer review, if it was tracked at all.

How we selected these platforms

We looked for four things:

  • Claims-based quality data the platform built itself, not self-reported ratings
  • A product built for employers and health plans, not consumer directories
  • The ability to plug into existing navigation or benefits workflows without a rip-and-replace
  • Evidence, ideally quantified, that using the platform actually changes cost or outcomes

Six platforms cleared that bar, ranked here from the most quality-analytics-focused to the most complementary.

6 doctor quality analytics platforms to know in 2026

1. Garner Health

Garner Health built its entire product around one question: which doctors, specifically, produce better outcomes at lower cost? Its scoring engine runs claims data through more than 550 clinical metrics it built in-house, drawing on a database of over 60 billion medical records, to rank physicians within their own specialty and market. Employers use the results to reward employees for choosing top-performing doctors, usually by covering most or all of the resulting out-of-pocket costs, without narrowing the network or restricting anyone’s choice.

The approach appears to be working at a scale that’s hard to ignore. Garner reports that employers using its platform see an average 12% reduction in total healthcare spend in the first year, and employees who choose a high-performing provider pay roughly 80% less out of pocket than they otherwise would. The company closed a $100 million Series E at a $2.74 billion valuation in May 2026, just three months after a $118 million Series D, a pace of investment that reflects how much appetite employers have for this exact category.

2. Embold Health

Where Garner scores individual doctors, Embold Health has taken the model a step further and built a health plan around it. Embold Edge, launched in 2026, analyzes 21 specialties and 68 sub-specialties using data spanning more than 230 million people, then structures member copays to reward high-quality choices without requiring employers to disrupt their existing network or carrier relationships. Its underlying bet: most healthcare waste traces back to low-quality care at the start of a patient’s journey rather than overpricing further downstream, so fixing the first referral fixes a lot of what follows.

3. Ribbon Health

Ribbon Health operates further upstream from the case manager, supplying the provider data (insurance participation, cost estimates, quality scores, and patient experience) that other platforms and health plans build their own navigation tools on top of, rather than selling directly to members itself. If you’ve used a “find a doctor” tool from a health plan or a digital navigation vendor recently, there’s a reasonable chance Ribbon’s data powered it behind the scenes.

4. Included Health

Included Health bundles quality-based referrals into a much broader navigation and virtual care platform. Its Provider Connect feature routes members toward high-quality, cost-effective providers automatically as part of the standard member journey. Care coordination, virtual visits, benefits navigation, and referral steering all live in one product, rather than requiring a separate vendor for each.

5. Quantum Health

Quantum Health takes a similar bundled approach through its Care Finder tool, which surfaces provider search and quality data directly inside its broader healthcare navigation platform. For organizations that already route members through Quantum Health for case management and benefits navigation, Care Finder adds the quality layer without introducing a separate point solution.

6. Turquoise Health

Quality data only tells half the value-based care story. Turquoise Health fills in the other half: rate transparency and contract intelligence that show what providers are actually paid under negotiated agreements. Pairing that pricing data with a quality score from one of the platforms above gets closer to a true value calculation. A genuinely high-value doctor is one who scores well on outcomes and isn’t wildly overpriced relative to peers.

Choosing the right platform for your organization

The right fit depends on what you’re already running. Organizations with an existing navigation vendor that just want to layer in quality scoring are usually better served by a pure-play option like Garner Health or Embold Health. Organizations building navigation and referral management from scratch tend to gravitate toward a bundled platform like Included Health or Quantum Health instead. Vendors and health plans building their own tools look to infrastructure providers like Ribbon Health for the underlying data.

Turquoise Health belongs in the stack alongside any of the above, since cost transparency and quality analytics answer different questions. Worth asking before signing anything: how the platform’s data reaches the people making referral decisions day to day. A quality score buried in a quarterly report to HR doesn’t change a single referral. A quality score surfaced inside the tool a case manager already uses at the point of referral does, and that distinction matters more than any single feature comparison.

Frequently asked questions

What is doctor quality analytics?

Doctor quality analytics is the practice of measuring an individual physician’s performance, including complication rates and avoidable readmissions, using claims data, then scoring that physician against peers in the same specialty and market. It replaces network directories, which only confirm insurance participation, with an evidence-based answer to whether a specific doctor delivers better results.

How do case managers use provider quality data in referrals and care coordination?

Case managers use provider quality scores to steer referrals toward physicians with better documented outcomes, rather than relying solely on network status or personal familiarity. Combined with a patient’s specific clinical needs and plan design, quality data helps a case manager justify a referral choice on evidence, which matters increasingly as employers tie benefits design to demonstrated cost and outcome performance.

Do doctor quality platforms only work for large self-insured employers?

No, though large self-insured employers were the earliest and most visible adopters because they bear healthcare costs directly and can redesign benefits without an insurer’s approval. Health plans, associations, and mid-market employers now access the same underlying quality data through partnerships and smaller-scale deployments, so the category isn’t limited to the biggest balance sheets anymore.

 

Author bio

Cassandra Rosas is a content writer who loves to cover topics related to healthcare software and AI, employee benefits, and new healthcare trends emerging in the industry. In her spare time she enjoys hiking in the mountains and spending time outdoors.

 

Please also review AIHCP’s Case Management Certification program and our CE courses as well, to see if they meet your academic and professional goals.  These programs are online and independent study and open to qualified professionals seeking a four year certification